Philippe Archinard
Director/Board Member at GENEURO SA
Net worth: 3 260 $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Alexandre Mérieux | M | 50 |
Advanced BioScience Laboratories, Inc.
Advanced BioScience Laboratories, Inc. Medical/Nursing ServicesHealth Services Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD.
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | 20 years |
Hedi Brahim | M | 43 |
Transgene, Inc.
Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd.
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | 6 years |
Alain Mérieux | M | 85 |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium
Advanced BioScience Laboratories, Inc.
Advanced BioScience Laboratories, Inc. Medical/Nursing ServicesHealth Services Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD.
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | 33 years |
Jean-Luc Bélingard | M | 74 |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | 18 years |
Géraldine Le Duc | M | - | 9 years | |
Eric Soyer | M | 57 | 1 years | |
Sylvain Morgeau | M | 44 | 13 years | |
Thibaut du Fayet | M | 56 | 1 years | |
Pierre Boulud | M | 52 | 8 years | |
Agnès Lemarchand | F | 69 |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium | 10 years |
Lucie Larguier | F | - | 8 years | |
Harold Y. H. Boël | M | 59 |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium | 12 years |
Fanny Letier | F | 45 |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium | 7 years |
Jesús Martin-Garcia | M | 62 | 18 years | |
Hervé Perron | M | 66 | 18 years | |
Jarlath Keating | M | - |
Advanced BioScience Laboratories, Inc.
Advanced BioScience Laboratories, Inc. Medical/Nursing ServicesHealth Services Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD. | 6 years |
Marie-Hélène Habert-Dassault | F | 59 |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium | 12 years |
Marie-Paule Kieny | F | 68 |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium | 7 years |
Alessandro Riva | M | 63 | 2 years | |
Sandrine Flory | F | - |
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | 10 years |
Michel Dubois | M | 81 | 18 years | |
Jean-Luc Poyet | M | - |
Jalon Therapeutics
Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison. | - |
Stéphane Boissel | M | 56 |
Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd.
Transgene, Inc.
| 5 years |
Hélène Sicard | F | - |
Jalon Therapeutics
Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison. | - |
David Loison | M | - |
Jalon Therapeutics
Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison. | - |
Laurence Espinasse | F | - |
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | 3 years |
Caroline Cayre | F | - | 5 years | |
Bernard Sinou | M | - |
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | - |
Robert Sebbag | M | 73 | 1 years | |
Jean-Yves Blay | M | 61 | 2 years | |
Christiaan Jansen | M | - |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium | - |
Bertrand Lepine | M | - |
Fabentech SAS
Fabentech SAS Medical/Nursing ServicesHealth Services Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France. | 15 years |
Nathalie Garçon | F | - |
BioAster
BioAster Miscellaneous Commercial ServicesCommercial Services BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon. | - |
Stéphane Legastelois | M | 64 |
BioAster
BioAster Miscellaneous Commercial ServicesCommercial Services BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon.
Jalon Therapeutics
Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison. | - |
Olivier Tillement | M | - | 9 years | |
John Felitti | M | 54 | 8 years | |
Valérie Leyldé | F | - | - | |
Carol Stuckley | F | 68 | 1 years | |
Frédéric Besème | M | 67 |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium | 6 years |
Maya Said | M | 47 | 7 years | |
Marie-Yvonne Landel-Meunier | F | 71 | 7 years | |
Giacomo di Nepi | M | 72 | 9 years | |
Martine George | M | 76 | 1 years | |
Eric Jean Marie Leire | M | 66 | 1 years | |
Hervé Eloi Dominique Brailly | M | 62 | 5 years | |
Guillaume Bouhours | M | 47 | 6 years | |
Frederic Hammel | M | - |
Fabentech SAS
Fabentech SAS Medical/Nursing ServicesHealth Services Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France. | - |
Jérôme Tiollier | M | 65 |
Jalon Therapeutics
Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison. | - |
Dominique Takizawa | F | 67 |
Advanced BioScience Laboratories, Inc.
Advanced BioScience Laboratories, Inc. Medical/Nursing ServicesHealth Services Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD. | 22 years |
Gordon Francis | M | 75 | 9 years | |
Renita Johnson-Leva | F | - |
Advanced BioScience Laboratories, Inc.
Advanced BioScience Laboratories, Inc. Medical/Nursing ServicesHealth Services Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD. | 20 years |
Michel Baguenault de Puchesse | M | 54 |
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | - |
Hilde Windels | F | 59 | 1 years | |
Benoît Habert | M | 59 | 24 years | |
Albert Saporta | M | 73 |
Fabentech SAS
Fabentech SAS Medical/Nursing ServicesHealth Services Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France. | - |
Philippe Boucheron | M | - | 5 years | |
Charles Cooper | M | - | - | |
Anke Post | M | - | - | |
Miguel Payró | M | 62 | 9 years | |
Karine Charton | M | - | 1 years | |
Vincent Carrère | M | - | - | |
Pascal Birman | M | - | 1 years | |
Philippe Dhenein | M | - |
BioAster
BioAster Miscellaneous Commercial ServicesCommercial Services BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon. | - |
Damien Chaussabel | M | - |
BioAster
BioAster Miscellaneous Commercial ServicesCommercial Services BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon. | - |
Marc Le Bozec | M | - | 5 years | |
Anne O' Garra | F | - |
BioAster
BioAster Miscellaneous Commercial ServicesCommercial Services BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon. | - |
Etienne Thiry | M | - |
BioAster
BioAster Miscellaneous Commercial ServicesCommercial Services BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon. | - |
Marie Chatot | F | - |
BioAster
BioAster Miscellaneous Commercial ServicesCommercial Services BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon. | - |
Yasha Mitrotti | M | - | - | |
Leila Nicolas | F | - | 1 years | |
Franck Lescure | M | - |
Fabentech SAS
Fabentech SAS Medical/Nursing ServicesHealth Services Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France. | - |
Anne de Chiffrevillle | F | - |
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | - |
Marc Eloit | M | - |
BioAster
BioAster Miscellaneous Commercial ServicesCommercial Services BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon. | - |
Luc Boblet | M | - |
BioAster
BioAster Miscellaneous Commercial ServicesCommercial Services BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon. | - |
Gwenaël Hamon | M | - |
Fabentech SAS
Fabentech SAS Medical/Nursing ServicesHealth Services Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France. | - |
Marc Bonneville | M | 65 |
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | 11 years |
Nitza Thomasson-Perret | M | 51 | 5 years | |
Jérôme Bailly | M | 45 | 1 years | |
Céline Breda | F | 54 | 1 years | |
Jean-Jacques Laborde | M | 79 |
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | 10 years |
Gil Beyen | M | 62 | 1 years | |
Ajay P. Bhale | M | - |
Advanced BioScience Laboratories, Inc.
Advanced BioScience Laboratories, Inc. Medical/Nursing ServicesHealth Services Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD. | 19 years |
Andrew A. Arrage | M | - |
Advanced BioScience Laboratories, Inc.
Advanced BioScience Laboratories, Inc. Medical/Nursing ServicesHealth Services Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD. | - |
Yannick Plétan | M | - | 5 years | |
Jennifer Zinn | F | - | 1 years | |
Guillaume Hemmerlé | M | 50 |
Fabentech SAS
Fabentech SAS Medical/Nursing ServicesHealth Services Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France. | 10 years |
Jean Christophe Rain | M | - |
Jalon Therapeutics
Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison. | - |
Pierre Charbonnier | M | 58 | - | |
James Wentworth | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Georges Hibon | M | 86 | 10 years | |
Paul Magrez | M | - |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 6 years |
Antoine Béret | M | 79 | - | |
Henri Thomasson | M | - | 28 years | |
Michel Angé | M | 84 | - | |
Jean Bizzari | M | 69 | - | |
Pierre-Patrick Hurteloup | M | 74 | - | |
Laurence Zitvogel | M | 60 | - | |
Philippe Gillet | M | 66 | - | |
Esther Wick | F | - | - | |
Gentiane Gorlier | M | - | 7 years |
Statistics
Country | Connections | % of total |
---|---|---|
France | 88 | 88.00% |
Belgium | 11 | 11.00% |
United States | 9 | 9.00% |
Switzerland | 8 | 8.00% |
China | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Philippe Archinard
- Personal Network